Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

What condition was this medication prescribed to treat?

What Type of Incident Did You have (Heart Attack, Stroke, etc)

Incident Date 

How Long Were You On Vytorin Before The Incident Occured

If other, please explain: 

Did insurance cover your medication?

What was your total out of pocket expense?

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Vytorin Named in 100+ Lawsuits, Justice Department Investigation

Dec 2, 2008 | Parker Waichman LLP

Vytorin is a combination of the statin Zocor and the cholesterol-lowering drug Zetia.  Vytorin has been under the microscope since the ENHANCE study, which found the drug was ineffective in preventing clogged arteries, was released last January.    Merck and Schering-Plough delayed releasing ENHANCE for more than a year – something critics have likened to fraud.  The delay prompted a Congressional investigation into the way Merck and Schering-Plough handled the ENHANCE findings.

According to Merck's SEC filing, the controversy over ENHANCE has resulted in more than 140 class action lawsuits that name Merck and its partner, Schering-Plough, as defendants.  According to the Associated Press, some of the lawsuits allege consumer fraud, while others involve claims for personal injury or seek medical monitoring for people who used Vytorin.

The SEC filing also confirms that the companies' promotion of Vytorin is the subject of a Justice Department investigation.  According to the Associated Press, that probe is focusing on whether the companies' promotions made false claims to federal health care programs.

News of the lawsuits and investigation is only the latest bad news involving Vytorin, which once promised to be a blockbuster for Merck and Schering-Plough.  Vytorin took another hit over the summer, when the SEAS study was released.  SEAS was designed to see if the drug helped people with aortic stenosis avoid heart attacks.  Not only did SEAS show that Vytorin offered no additional heart attack prevention, but Vytorin patients enrolled in the study had higher rates of cancer than those taking a placebo. Congress recently expanded its Vytorin investigation to include the handling of SEAS.

Other articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo